News archive
Showing 672 results
November 2021
-
Media ReleaseNovartis iptacopan meets primary endpoints in Phase II study in rare kidney disease C3 glomerulopathy (C3G)
-
Media ReleaseNovartis iptacopan meets primary endpoints in Phase II study in rare kidney disease C3 glomerulopathy (C3G)Statistically significant and clinically important reductions in proteinuria were achieved for the primary endpoint for patients with C3G(1) Additionally, statistically significant reduction in C3…
-
Media ReleaseFDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
-
Media ReleaseFDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemiaScemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine…
October 2021
-
Media ReleaseKesimpta® (ofatumumab) data at ECTRIMS highlights preservation of IgG levels and safety experience over extended exposure (~3.5 years) in people living with relapsing multiple sclerosisALITHIOS Phase IIIb open-label extension study data based on ~3.5 years of exposure demonstrated that mean immunoglobulin G (IgG) levels in patients treated with Kesimpta remained stable, and there…
-
Media ReleaseNovartis announces FDA and EMA filing acceptances of BEOVU® for patients with diabetic macular edemaRegulatory decisions for BEOVU® (brolucizumab-dbll) in diabetic macular edema (DME) are expected in mid-2022 in the US and Europe DME is the leading cause of blindness in adults in developed…
September 2021
-
Media ReleaseNovartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
-
Media ReleaseNovartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancerWith the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced…
-
Media ReleaseNovartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)
-
Media ReleaseNovartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissues At 24…
August 2021
-
Media ReleaseNovartis launches "Meet The PROS" to raise awareness and support education for PIK3CA-Related Overgrowth Spectrum (PROS)
-
Media ReleaseNovartis launches "Meet The PROS" to raise awareness and support education for PIK3CA-Related Overgrowth Spectrum (PROS)PROS is a spectrum of at least 13 rare conditions driven by mutations in the PIK3CA gene, typically associated with tissue overgrowth, vascular malformations, and neurological disorders New…